From L-R: Johnson & Johnson CEO Joaquin Duato, Merck CEO Rob Davis and Bristol Myers Squibb CEO Chris Boerner testify in front of the Senate HELP Committee on Feb. 8, 2024 (Kevin Dietsch/Getty Images)

February 8, 2024 04:09 PM ESTUpdated 04:48 PM

Senate grills pharma CEOs, who emerge from hearing on drug prices largely unscathed

Nicole DeFeudis

Editor

For about three hours on Thursday, senators pressed the CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson on why US drugs cost so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senate grills pharma CEOs, who emerge from hearing on drug prices largely unscathed

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Sen­ate grills phar­ma CEOs, who emerge from hear­ing on drug prices large­ly un­scathed

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Senate grills pharma CEOs, who emerge from hearing on drug prices largely unscathed